

Dissolve the total contents of the ampoule with 0.5ml of sterile distilled water. Rinse the ampoule with 0.4ml of sterile distilled water and make up the total volume to 1ml with sterile distilled water. This solution should now contain IL-29 at a concentration of 5,000 U/ml. Use carrier protein where extensive dilution is required. It is recommended that the IL-29 solution be used immediately or stored as indicated in section5.

8. STABILITY

Reference materials are held at NIBSC within assured, temperaturecontrolled storage facilities and they should be stored on receipt as indicated on the label. It is the policy of WHO not to assign an expiry date to their international reference materials. Accelerated degradation studies have indicated that this material is suitably stable, when stored at -20°C or below, for the assigned values to remain valid until the material is withdrawn or replaced. These studies have also shown that the material is suitably stable for shipment at ambient temperature without any effect on the assigned values. Users who have data supporting any deterioration in the characteristics of any reference preparation are encouraged to contact NIBSC.

9. REFERENCES

This reference reagent was produced under WHO guidelines cited in the WHO Technical Reports Series, no. 925, 2005.

Report on a Collaborative study for proposed 1st WHO reference reagent for human Interleukin-29 WHO/BS/2012.2197

http://www.who.int/biologicals/expert_committee/BS_2197_Proposed_1st_W HO_reference_reagent_for_human_interleukin-29_(IL-29).pdf

10. ACKNOWLEDGEMENTS

N/A

11. FURTHER INFORMATION

Further information can be obtained as follows; This material: enquiries@nibsc.org WHO Biological Standards: http://www.who.int/biologicals/en/ JCTLM Higher order reference materials: http://www.bipm.org/en/committees/jc/jctlm/ Derivation of International Units: http://www.nibsc.org/standardisation/international_standards.aspx Ordering standards from NIBSC: http://www.nibsc.org/products/ordering.aspx NIBSC Terms & Conditions: http://www.nibsc.org/terms_and_conditions.aspx

12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET



WHO Reference Reagent Interleukin-29 (Interferon Lamda 1) NIBSC code: 10/176 Instructions for use (Version 1.0, Dated 12/04/2013)

1. INTENDED USE

This material is intended as a biological reference standard in bioassays for IL-29 (Interferon Lamda 1).

2. CAUTION

This preparation is not for administration to humans or animals in the human food chain.

The preparation contains human and bovine source material. The preparation contains an excipient of human origin which has been tested and found negative for HBsAg and HIV antibody. The preparation has subsequently been tested and found negative for anti-HCV and HCV RNA by PCR. The bovine casein used as an excipient was sourced from a country where bovine spongiform encephalopathy (BSE) has not been found. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE

The assigned potency of the preparation is 5,000 units of biological activity per ampoule.

4. CONTENTS

Country of origin of biological material: United Kingdom. Each ampoule contains the residue after freeze-drying of 1ml of phosphate buffered saline that contained:

Approximately 500 nanograms of recombinant human IL-29 1.0% human serum albumin

0.3% bovine casein

The IL-29 protein was expessed in E.coli.

The ampoule does not contain bacteriostat.

5. STORAGE

For economy of use, it is recommended that the solution be sub-divided into several small aliquots and stored at -40°C or below. Avoid repeated thawing/freezing. Unopened ampoules should be stored at -20°C. Please note: because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.

6. DIRECTIONS FOR OPENING

DIN ampoules have an 'easy-open' coloured stress point, where the narrow ampoule stem joins the wider ampoule body. Various types of ampoule breaker are available commercially. To open the ampoule, tap the ampoule gently to collect material at the bottom (labelled) end and follow manufactures instructions provided with the ampoule breaker.

7. USE OF MATERIAL

No attempt should be made to weigh out any portion of the freeze-dried material prior to reconstitution

National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, EN6 3QG. T +44 (0)1707 641000, nibsc.org WHO International Laboratory for Biological Standards, UK Official Medicines Control Laboratory

Medicines & Healthcare products Regulatory Agency



Physical and Chemical properties		
Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not Physical appearance: White powder	Corrosive:	No
Stable: Yes	Oxidising:	No
Hygroscopic: No	Irritant:	No
Flammable: No	Handling:	See caution, Section 2
Other (specify): Co	ontains material	of human and bovine origin
	Toxicological p	properties
Effects of inhalation: Not established, avoid inhalation		
Effects of ingestion: Not established, avoid ingestion		
Effects of skin absorption: Not established, avoid contact with skin		
Suggested First Aid		
Inhalation: Seek medical advice		
Ingestion: Seek medical advice		
Contact with eyes: W medical advice	ash with copiou	s amounts of water. Seek
Contact with skin: W	ash thoroughly	with water.
Action on Spillage and Method of Disposal		
Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate disinfectant. Rinse area with an appropriate disinfectant followed by water. Absorbent materials used to treat spillage should be treated as biological waste.		

15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) ("Conditions") apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. INFORMATION FOR CUSTOMS USE ONLY

Country of origin for customs purposes*: United Kingdom * Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying. Net weight: 0.5 gram Toxicity Statement: Toxicity not assessed

Veterinary certificate or other statement if applicable.

Attached: No

17. CERTIFICATE OF ANALYSIS

National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, EN6 3QG. T +44 (0)1707 641000, nibsc.org WHO International Laboratory for Biological Standards, UK Official Medicines Control Laboratory

